For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $78.94 in the prior trading day, ANI Pharmaceuticals Inc (NASDAQ: ANIP) closed at $78.43, down -0.65%. In other words, the price has decreased by -$0.65 from its previous closing price. On the day, 0.63 million shares were traded. ANIP stock price reached its highest trading level at $80.285 during the session, while it also had its lowest trading level at $77.41.
Ratios:
Our goal is to gain a better understanding of ANIP by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.27. For the most recent quarter (mrq), Quick Ratio is recorded 2.04 and its Current Ratio is at 2.58. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.22.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $84.
On March 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $80.
On March 12, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $85.JP Morgan initiated its Overweight rating on March 12, 2025, with a $85 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 18 ’25 when Davis Krista sold 1,622 shares for $82.40 per share. The transaction valued at 133,653 led to the insider holds 58,564 shares of the business.
Cook Meredith sold 400 shares of ANIP for $32,928 on Dec 12 ’25. The SR. VP, GENERAL COUNSEL & SEC. now owns 74,874 shares after completing the transaction at $82.32 per share. On Dec 05 ’25, another insider, TANNENBAUM RENEE P, who serves as the Director of the company, sold 1,800 shares for $81.15 each. As a result, the insider received 146,070 and left with 25,157 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANIP now has a Market Capitalization of 1761394176 and an Enterprise Value of 1999624960. As of this moment, ANI’s Price-to-Earnings (P/E) ratio for their current fiscal year is 48.10, and their Forward P/E ratio for the next fiscal year is 9.20. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.13 while its Price-to-Book (P/B) ratio in mrq is 3.48. Its current Enterprise Value per Revenue stands at 2.418 whereas that against EBITDA is 13.784.
Stock Price History:
The Beta on a monthly basis for ANIP is 0.51, which has changed by 0.4364469 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, ANIP has reached a high of $99.50, while it has fallen to a 52-week low of $52.74. The 50-Day Moving Average of the stock is -7.73%, while the 200-Day Moving Average is calculated to be 1.39%.
Shares Statistics:
The stock has traded on average 395.08K shares per day over the past 3-months and 455510 shares per day over the last 10 days, according to various share statistics. A total of 22.46M shares are outstanding, with a floating share count of 19.25M. Insiders hold about 14.30% of the company’s shares, while institutions hold 92.30% stake in the company. Shares short for ANIP as of 1765756800 were 2668488 with a Short Ratio of 6.75, compared to 1763078400 on 2485416. Therefore, it implies a Short% of Shares Outstanding of 2668488 and a Short% of Float of 14.799999999999999.
Earnings Estimates
. The current market rating for ANI Pharmaceuticals Inc (ANIP) reflects the collective analysis of 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.62, with high estimates of $1.94 and low estimates of $1.44.
Analysts are recommending an EPS of between $7.65 and $7.21 for the fiscal current year, implying an average EPS of $7.52. EPS for the following year is $8.53, with 8.0 analysts recommending between $9.73 and $7.53.
Revenue Estimates
7 analysts predict $233.32M in revenue for. The current quarter. It ranges from a high estimate of $242.14M to a low estimate of $229.7M. As of. The current estimate, ANI Pharmaceuticals Inc’s year-ago sales were $190.57MFor the next quarter, 7 analysts are estimating revenue of $207.72M. There is a high estimate of $222.03M for the next quarter, whereas the lowest estimate is $195M.
A total of 7 analysts have provided revenue estimates for ANIP’s current fiscal year. The highest revenue estimate was $878.44M, while the lowest revenue estimate was $866M, resulting in an average revenue estimate of $869.63M. In the same quarter a year ago, actual revenue was $614.38MBased on 7 analysts’ estimates, the company’s revenue will be $955.03M in the next fiscal year. The high estimate is $1.01B and the low estimate is $913M.
